Your browser doesn't support javascript.
loading
Prevalence of cutaneous manifestations and myositis-specific antibodies in COVID-19 patients and Anti-PL7 antibodies association with pulmonary radiological severity: A retrospective study.
Oddenino, Giorgio Alberto; Canepa, Paola; Cozzani, Emanuele; Gasparini, Giulia; Garlaschi, Alessandro; Roccatagliata, Luca; Schiavetti, Irene; Parodi, Aurora.
Afiliación
  • Oddenino GA; Section of Dermatology, Dipartimento di Scienze della Salute (DiSSal), University of Genoa, Genoa, Italy.
  • Canepa P; IRCCS Ospedale Policlinico San Martino, Dermatology Unit, Genoa, Italy.
  • Cozzani E; IRCCS Ospedale Policlinico San Martino, Dermatology Unit, Genoa, Italy.
  • Gasparini G; Section of Dermatology, Dipartimento di Scienze della Salute (DiSSal), University of Genoa, Genoa, Italy.
  • Garlaschi A; IRCCS Ospedale Policlinico San Martino, Dermatology Unit, Genoa, Italy.
  • Roccatagliata L; Section of Dermatology, Dipartimento di Scienze della Salute (DiSSal), University of Genoa, Genoa, Italy.
  • Schiavetti I; IRCCS Ospedale Policlinico San Martino, Dermatology Unit, Genoa, Italy.
  • Parodi A; IRCCS Ospedale Policlinico San Martino, Dermatology Unit, Genoa, Italy.
Int J Immunopathol Pharmacol ; 38: 3946320241260295, 2024.
Article en En | MEDLINE | ID: mdl-39052920
ABSTRACT

BACKGROUND:

Dermatomyositis (DM) is an idiopathic immune-mediated myopathy, and may involve many organs, including muscles, skin and lungs. Myositis-specific autoantibodies (MSAs) are a useful aid in diagnosis DM and identifying its clinical subtype. During the COVID-19 pandemic, several studies found clinical similarities regarding lung involvement in both COVID-19 and DM. Such similarities have prompted speculation of a common pathogenetic mechanism. Indeed, viral infections are well-known triggers of autoimmune diseases. This prompted us to investigate whether circulating MSAs could be markers of the severity of lung involvement and of clinical outcome in COVID-19 patients. Moreover, we investigated the presence of cutaneous signs of DM in COVID-19 patients.

METHODS:

We conducted a retrospective cohort study on 178 hospitalized patients affected by COVID-19. The diagnosis was confirmed by naso-pharyngeal swab positivity for SARS-CoV-2. The severity of lung involvement was assessed by assigning to each patient a radiological score ranging from 1 to 4, based on chest imaging (chest X-rays or CT scans). Serum samples were tested for MSAs.

RESULTS:

Anti-PL-7 antibodies were detected in 10.1% of patients and were found to be associated with an increased risk of severe pulmonary involvement (p = 0.019) and a worse prognosis in COVID-19 patients. Cutaneous lesions were observed in 26.4% of patients. However, none were cutaneous manifestations of DM.

CONCLUSIONS:

The detection of anti-PL7 antibodies might predict severe pulmonary involvement and a worse prognosis in COVID-19 patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Autoanticuerpos / Índice de Severidad de la Enfermedad / COVID-19 Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Immunopathol Pharmacol Asunto de la revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA / PATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Autoanticuerpos / Índice de Severidad de la Enfermedad / COVID-19 Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Immunopathol Pharmacol Asunto de la revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA / PATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido